Gilead: 4Q EPS, Revenue Beat; 2016 Sales Forecast Looks Light

Gilead Sciences (GILD) posted better-than-expected fourth-quarter financial results as sales of its hepatitis C drugs exceeded forecasts. Still, the biotech giant gave back after-hour gains as full-year sales forecasts failed to impress. Gilead also boosted its dividend and almost doubled its share repurchase plan. At a recent $83, the shares were up 0.4% after earlier […]